Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACROSS-TROP2 biomarker study in HR+/HER2- metastatic breast cancer treated with sacituzumab govitecan
2023-505385-28-00Phase 2Authorised
- Sponsor
- SOLTI
- Start
- Oct 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in breast cancer, sponsored by SOLTI. Primary endpoint: Mean change in CelTIL score between baseline and C2D1. Planned start Oct 2023; status: authorised.
02
Drugs
sacituzumab govitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-505385-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505385-28-00.